CLSN has been the subject of several other research reports. Brookline Capital Management reaffirmed a buy rating on shares of Celsion in a report on Thursday, July 25th. Zacks Investment Research raised shares of Celsion from a sell rating to a hold rating in a report on Tuesday, July 16th.
Celsion stock traded up $0.03 during mid-day trading on Thursday, hitting $1.74. The stock had a trading volume of 93,007 shares, compared to its average volume of 82,229. The stock has a market cap of $35.85 million, a price-to-earnings ratio of -2.56 and a beta of 1.94. The company has a debt-to-equity ratio of 0.51, a current ratio of 4.22 and a quick ratio of 4.22. The company has a 50 day moving average of $1.78. Celsion has a one year low of $1.35 and a one year high of $3.10.
An institutional investor recently raised its position in Celsion stock. BlackRock Inc. increased its position in Celsion Co. (NASDAQ:CLSN) by 21.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 142,426 shares of the biotechnology company’s stock after buying an additional 25,548 shares during the period. BlackRock Inc. owned about 0.76% of Celsion worth $202,000 at the end of the most recent quarter. 4.76% of the stock is currently owned by institutional investors.
Celsion Company Profile
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.